TRAC

TRAC Product List

Product Category
Protein (2)
Product Status
Launched (2)
Species
Human (2)
Tag
His Tag (1)Fc Tag (1)
Conjugate
Unconjugated (2)

Cat. No.	Species	Host	Product Description	Structure	Purity	Feature	Order Now
TRC-H5257	Human	HEK293	Human TRAC Protein, Fc Tag				Add to Cart
TRC-H52H3	Human	HEK293	Human TRAC Protein, His Tag				Add to Cart

Total: 2

TRAC Background

The transmembrane protein, TCR, comprise of two disulphide-linked polypeptide chains: a α and β chain, a γ and δ chain. Each polypeptide chain consists of a variable and a constant region. TRAC is the constant region of T-cell receptor (TCR) alpha chain. TRAC is presented on the surface of T cell and recognized peptide-major histocompatibility (MH) (pMH) that are displayed by antigen presenting cells (APC). TRAC is participate in adaptive immune response and has been well-studied in T cell therapy.

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
MT-2765	MT-2765	Phase 3 Clinical	Mitsubishi Tanabe Pharma Corp	Hypertension	Details
SP-20104 (Sarfez Pharmaceuticals)	SP-20104	Phase 2 Clinical	1 A Pharma Gmbh	Glomerulosclerosis, Focal Segmental	Details
Imarikiren hydrochloride	TAK-272; SCO-272	Phase 2 Clinical	Takeda Pharmaceutical Co Ltd	Kidney Diseases; Hypertension; Diabetic Nephropathies; Hepatic Insufficiency	Details

Marketed Drug Information

English Name	Research Code	Highest Development Stage	Company	Earliest Brand Name	Earliest Approval Country	Earliest Indication	Earliest Approval Company	Earliest Approval Date	Indication	Clinical Trial
Aliskiren Hemifumarate/Amlodipine Besilate/Hydrochlorothiazide		Approved	Novartis Pharma Ag	Rasitrio, Amturnide	United States	Hypertension	null	2010-12-21	Hypertension; Essential Hypertension	Details
Aliskiren Hemifumarate	SPP-100; SPP-100A; SPP-100B; CGP-60536; CGP-60536B	Approved	Novartis Pharma Ag	Enviage, Rasilez, Riprazo, Sprimeo, Tekturna, 锐思力	United States	Hypertension	Noden Pharma Dac	2007-03-05	Myocardial Ischemia; Heart Failure; Myocardial Infarction; Diabetes Mellitus, Type 2; Glomerulonephritis, IGA; Coronary Artery Disease; Hypertension; Hypertrophy, Left Ventricular; Diabetic macular oedema; Cardiovascular Diseases; Diabetic Nephropathies; Essential Hypertension; Overweight; Diabetes Mellitus; Kidney Failure, Chronic	Details
Aliskiren		Approved			Mainland China	Essential Hypertension	Novartis Pharma Ag	2010-03-26	Essential Hypertension	Details